Description
OLMEROOT-A
Olmesartan Medoxomil and Amlodipine Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Olmesartan Medoxomil IP — 20 mg
Amlodipine IP — 5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
OLMEROOT-A is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil and Amlodipine, formulated for the effective management of hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the sustained vasodilatory action of Amlodipine, resulting in superior antihypertensive efficacy and enhanced target organ protection.
Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, improves arterial compliance, and provides sustained 24-hour blood pressure control.
OLMEROOT-A is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, metabolic syndrome, obesity, elderly hypertension, left ventricular hypertrophy, and patients requiring combination antihypertensive therapy.
Technical Knowledge of Olmesartan Medoxomil and Amlodipine
Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling.
Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval.
The combination of Olmesartan and Amlodipine provides complementary antihypertensive mechanisms with enhanced cardiovascular and renal protective benefits.
Mechanism of Action
Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.
Amlodipine relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive action.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Supports cardiovascular and renal protection
Improves vascular compliance and endothelial function
Reduces peripheral vascular resistance
Effective in diabetic and chronic kidney disease patients
Convenient once-daily dosing
Suitable for long-term hypertension management under medical supervision
Clinical Applications
OLMEROOT-A is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with metabolic syndrome, elderly hypertension, left ventricular hypertrophy, and long-term cardiovascular risk reduction.
Facts About Olmesartan Medoxomil and Amlodipine
Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Amlodipine is one of the most extensively prescribed calcium channel blockers worldwide and provides effective long-term blood pressure control. The combination is widely recommended for patients requiring dual antihypertensive therapy because of its excellent efficacy, tolerability, and target organ protective effects.
Key Facts
ARB and calcium channel blocker combination therapy
Olmesartan Medoxomil for vascular and renal protection
Amlodipine for sustained arterial vasodilation
Provides 24-hour comprehensive blood pressure control
Effective in hypertension with diabetes and chronic kidney disease
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
OLMEROOT-A is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose OLMEROOT-A for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil and Amlodipine Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
OLMEROOT-A from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Amlodipine formulation.